A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). MATERIALS AND METHODS: We conducted a multi-center randomized ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Kwai Han, Lee, Su Jin, Cho, Jinhyun, Lee, Ki Hyeong, Park, Keon Uk, Kim, Ki Hwan, Cho, Eun Kyung, Choi, Yoon Hee, Kim, Hye Ryun, Kim, Hoon-Gu, Ahn, Heui June, Lee, Ha Yeon, Yun, Hwan Jung, Kang, Jin-Hyoung, Jeong, Jaeheon, Choi, Moon Young, Jung, Sin-Ho, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473296/
https://www.ncbi.nlm.nih.gov/pubmed/30177585
http://dx.doi.org/10.4143/crt.2018.324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473296/
https://www.ncbi.nlm.nih.gov/pubmed/30177585
http://dx.doi.org/10.4143/crt.2018.324

Ejemplares similares